{"entity":{"id":"nct06834282","kind":"trial","name":"CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)","aka":[],"tldr":"A phase 1 trial of CER-1236 run by CERo Therapeutics Holdings, Inc., now recruiting.","summary":"CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF) is a phase 1 interventional study registered as NCT06834282 by CERo Therapeutics Holdings, Inc., with 18 participants planned, started 2025-04-07. Conditions recorded: AML, Acute Myeloid Leukemia and Refractory Acute Myeloid Leukemia. Interventions recorded: CER-1236, Cyclophosphamide, Fludarabine and Mesna.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06834282","url":"https://clinicaltrials.gov/study/NCT06834282"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml","mds","primary-myelofibrosis"],"sections":[],"technologies":[],"targets":[],"drugs":["cer-1236"],"companies":["cero-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06834282","phase":"1","setting":"Phase 1/1b First-in-human Study of Autologous Chimeric Engulfment Receptor T-Cell CER-1236 in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Myelofibrosis (CertainT-1)","sponsor":"CERo Therapeutics Holdings, Inc.","enrolled":18,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06834282/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"},{"id":"primary-myelofibrosis","kind":"cancer","name":"Primary myelofibrosis","route":"/cancers/primary-myelofibrosis/"}],"drug":[{"id":"cer-1236","kind":"drug","name":"CER-1236","route":"/drugs/cer-1236/"}],"company":[{"id":"cero-therapeutics","kind":"company","name":"CERo Therapeutics","route":"/companies/cero-therapeutics/"}]}}